Figure 3.

The effects of treatment with BCP on the inflammatory cell infiltration into the spinal cords and pathological score with H&E for enumerating infiltrating leukocytes; (A) The effects of DMF (60 mg/kg; 30 mg/kg twice a day; p.o.), BCP (2.5, 5 mg/kg/day; p.o.), and the combination of a CB₂ antagonist AM630 (1 mg/kg; i.p.) with BCP (5 mg/kg/day; p.o.) with BCP (5 mg/kg/day; p.o.) on the pathological score in EAE mice. (B) Sham group. (C) Vehicle. (D) DMF 60 mg/kg. (E) BCP 2.5 mg/kg. (F) BCP 5 mg/kg. (G) BCP 5 mg/kg + AM630; indicates lumbar spinal cord parts of H&E staining (100×); 0—without inflammation; 1—low inflammatory cell levels, 2—perivascular infiltrates; and 3—the extended intensity of perivascular cuffing with extension into contiguous tissue. Data were presented as mean ± range, n = seven animals per group, three to four fields of view per animal for each experiment protocol. Considering that data has non-parametric nature, data analysis was performed using the Kruskal–Wallis test and Dunn’s post hoc multiple comparisons test. (*) indicates the comparison between varying doses of BCP and DMF groups and the vehicle group, *: p < 0.05, and ***: p < 0.001.; (⁺) makes a comparison between the vehicle and sham groups, ⁺⁺⁺: p < 0.001.; ^# makes comparisons between BCP to DMF group in each graph, ^#: p < 0.05.